IP Library Granted Patent US 9,241,933
Granted Patent B2
US 9,241,933 · App. 14/473,245 · Granted Jan 26, 2016

Compositions for treating amyotrophic lateral sclerosis

Inventors: Daniel Cohen (Le Vesinet, FR); Serguei Nabirochkin (Chatenay Malabry, FR); Ilya Chumakov (Vaux le Penil, FR); Rodolphe Hajj (Saint Germain en Laye, FR)
Assignee: PHARNEXT
A61K31/44A61K31/185A61K31/195A61K31/197A61K45/06A61K9/2004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,241,933
App. No.
14/473,245
Granted
Jan 26, 2016
Kind
B2
Abstract

The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Claims (16)

1. A method of treating or reducing motor neuron degeneration in a subject having amyotrophic lateral sclerosis (ALS) or a related motor neuron disorder, the method comprising administering to the subject an effective amount of a synergistic combination of acamprosate and baclofen, or salts, or sustained-release formulations thereof.

2. The method of claim 1 , comprising administering to said subject baclofen, acamprosate and torasemide.

3. The method of claim 1 , comprising further administering to said subject riluzole, a salt thereof, or sustained-release formulation thereof.

4. The method of claim 1 , wherein the compounds are administered with a pharmaceutically acceptable carrier or excipient.

5. The method of claim 1 , wherein the compounds are formulated or administered together, separately or sequentially.

6. The method of claim 1 , wherein the compounds are administered repeatedly to the subject.

7. The method of claim 3 , wherein riluzole is administered in a dosage of less than 50 mg per day.

8. The method of claim 1 , wherein acamprosate is administered in a dosage of less than 50 mg per day.

9. The method of claim 1 , wherein baclofen is administered in a dosage of less than 30 mg per day.

10. The method of claim 1 , wherein said compounds are administered orally.

11. The method of claim 3 , wherein the combination of acamprosate and baclofen is administered orally and repeatedly every other day, alternately with riluzole.

12. The method of claim 1 , wherein the compounds are formulated together.

13. The method of claim 1 , wherein said related motor neuron disorder is a disorder selected from the group consisting of primary lateral sclerosis, progressive muscular atrophy, pseudobulbar palsy and progressive bulbar palsy, and fronto temporal dementia.

14. A composition comprising riluzole, or a salt, prodrug, derivative or sustained-release formulation thereof, in combination with a synergistic combination of baclofen and acamprosate, or salt(s), or sustained-release formulation thereof.

15. A tablet comprising riluzole and a synergistic combination of baclofen and acamprosate.

16. A unit dosage package comprising unit doses of i) a synergistic combination of acamprosate and baclofen and ii) riluzole, suitable for combined, separate or sequential administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 13, 2022
From: IPF MANAGEMENT S.A., AS BONDHOLDERS' REPRESENTATIVE
To: PHARNEXT S.A.
Reel/Frame 061081/0098 →
SECURITY INTEREST Recorded Sep 4, 2018
From: PHARNEXT S.A.
To: IPF MANAGEMENT S.A., AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 046775/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2014
From: COHEN, DANIEL; NABIROCHKIN, SERGUEI; CHUMAKOV, ILYA; HAJJ, RODOLPHE
To: PHARNEXT
Reel/Frame 034208/0724 →
Priority Claims (2)
EP 11305217 · Mar 1, 2011 · regional
EP 11305687 · Jun 6, 2011 · regional
Continuity (12)
Continuation In Part PCTEP2013054024 · Feb 28, 2013
Continuation In Part PCTEP2012053565 · Mar 1, 2012
Continuation In Part PCTEP2012053570 · Mar 1, 2012
Continuation In Part 14473245
Continuation In Part 14014650 · Aug 30, 2013
Continuation In Part PCTEP2012053565 · Mar 1, 2012
Continuation In Part 14473245
Continuation 13691981 · Dec 3, 2012
Continuation PCTEP2012053570 · Mar 1, 2012
Provisional Application 61468658 · Mar 29, 2011
Provisional Application 61493606 · Jun 6, 2011
Related Publication 20140371277A1 · Dec 18, 2014